About Philip Rye
This author has yet to write their bio.Meanwhile lets just say that we are proud Philip Rye contributed a whooping 11 entries.
Entries by Philip Rye
AlgiPharma has registered a new proprietary limited company in Melbourne, Australia.
An EU Horizon 2020 proposal (OligoGpivotalCF) submitted by a consortium assembled by AlgiPharma, has been successful in winning a grant of EUR 6 million to support AlgiPharma’s cystic fibrosis drug candidate OligoG through a pivotal clinical trial program.
AlgiPharma AS announced an agreement with Cystic Fibrosis Foundation (CFF), Bethesda, MD., that will provide up to $3 million to support further research and development of AlgiPharma’s drug candidate (OligoG) for the treatment of people with cystic fibrosis. This is in addition to more than $11.5 million already received from the Cystic Fibrosis Foundation for Phase 2 clinical work.
AlgiPharma has been awarded up to NOK 10 million from the Norwegian Research Council for the project “Novel alginate oligomer products for enhanced delivery across mucosal barriers (Mucos-ALG)”.
Hilde Morris has recently been appointed to replace our outgoing clinical director.
AlgiPharma collaboration wins Cardiff University’s prestigious Medical Innovation Award
AlgiPharma Announces $4 Million Award from Cystic Fibrosis Foundation Therapeutics to Advance Clinical Development of OligoG.
AlgiPharma now features on the Cystic Fibrosis Foundation (CFF) drug development pipeline
AlgiPharma secures new license agreement with NTNU for exclusive global rights.
Phone: +47 67545770